These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 9442782

  • 41. A comparison of the fixed combination of latanoprost and timolol with its individual components.
    Pfeiffer N, European Latanoprost Fixed Combination Study Group.
    Graefes Arch Clin Exp Ophthalmol; 2002 Nov; 240(11):893-9. PubMed ID: 12486510
    [Abstract] [Full Text] [Related]

  • 42. Efficacy and safety of the latanoprost/timolol maleate fixed combination vs concomitant brimonidine and latanoprost therapy.
    Stewart WC, Stewart JA, Day DG, Sharpe ED, Jenkins JN.
    Eye (Lond); 2004 Oct; 18(10):990-5. PubMed ID: 15037890
    [Abstract] [Full Text] [Related]

  • 43. Efficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: combined analysis of pooled data from two large randomized observer and patient-masked studies.
    Fechtner RD, McCarroll KA, Lines CR, Adamsons IA.
    J Ocul Pharmacol Ther; 2005 Jun; 21(3):242-9. PubMed ID: 15969642
    [Abstract] [Full Text] [Related]

  • 44. [A comparison between latanoprost and timolol in treatment of patients with primary open-angle glaucoma and ocular hypertension].
    Peng D, Li S, Li M, Shao H, Sun X, Sheng Y, Yu K, Fu P, Guo W, Meng F, Xu C, Zhu Z.
    Zhonghua Yan Ke Za Zhi; 2000 Jul; 36(4):285-8. PubMed ID: 11853616
    [Abstract] [Full Text] [Related]

  • 45. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide.
    Boyle JE, Ghosh K, Gieser DK, Adamsons IA.
    Ophthalmology; 1999 Dec; 106(12 Suppl):10-6. PubMed ID: 10598692
    [Abstract] [Full Text] [Related]

  • 46. Five-year, multicenter safety study of fixed-combination latanoprost/timolol (Xalacom) for open-angle glaucoma and ocular hypertension.
    Alm A, Grunden JW, Kwok KK.
    J Glaucoma; 2011 Dec; 20(4):215-22. PubMed ID: 20520568
    [Abstract] [Full Text] [Related]

  • 47. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
    LeBlanc RP.
    Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370
    [Abstract] [Full Text] [Related]

  • 48. Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study.
    Katz LJ, Rauchman SH, Cottingham AJ, Simmons ST, Williams JM, Schiffman RM, Hollander DA.
    Curr Med Res Opin; 2012 May; 28(5):781-8. PubMed ID: 22458918
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. The combination latanoprost-timolol versus twice daily 0.50% timolol administration either associated or not with latanoprost: efficacy and tolerability in the primary open-angle glaucoma.
    Pacella E, Pacella F, Cavallotti C, Librando A, Feher J, Pecori-Giraldi J.
    Eur Rev Med Pharmacol Sci; 2010 May; 14(5):477-80. PubMed ID: 20556928
    [Abstract] [Full Text] [Related]

  • 57. Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure.
    Bacharach J, Dubiner HB, Levy B, Kopczynski CC, Novack GD, AR-13324-CS202 Study Group.
    Ophthalmology; 2015 Feb; 122(2):302-7. PubMed ID: 25270273
    [Abstract] [Full Text] [Related]

  • 58. [Randomized parallel group study of 0.0015% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005% latanoprost ophthalmic solution)].
    Ge J, Li X, Sun X, He X, Zhang H.
    Zhonghua Yan Ke Za Zhi; 2015 Feb; 51(2):95-102. PubMed ID: 25907999
    [Abstract] [Full Text] [Related]

  • 59. Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with beta adrenergic antagonists. French Latanoprost Study Group, and the Swedish Latanoprost Study Group.
    Nordmann JP, Söderström M, Rouland JF, Malecaze F.
    Br J Ophthalmol; 2000 Feb; 84(2):181-5. PubMed ID: 10655195
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.